We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+10.75%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$3B
AUM Growth
-$85.7M
Cap. Flow
-$518M
Cap. Flow %
-17.24%
Top 10 Hldgs %
35.54%
Holding
152
New
30
Increased
26
Reduced
33
Closed
32

Top Buys

Rank Stock Value
1
VTRS icon
Viatris
VTRS
+$60.8M
2
ALPN
Alpine Immune Sciences Inc
ALPN
+$55.6M
3
TVTY
Tivity Health, Inc. Common Stock
TVTY
+$40.9M
4
TEVA icon
Teva Pharmaceuticals
TEVA
+$39.9M
5
DYAX
DYAX CORPORATION
DYAX
+$35.8M

Top Sells

Rank Stock Value
1
ASPX
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
+$446M
2
ABBV icon
AbbVie
ABBV
+$89.8M
3
ADVM
Adverum Biotechnologies
ADVM
+$85.8M
4
BLUE
bluebird bio
BLUE
+$47.9M
5
ACHN
Achillion Pharmaceuticals
ACHN
+$27.7M

Sector Composition

Rank Sector Weight
1 Healthcare 70.77%
2 Financials 3.42%
3 Technology 0.52%
4 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DSCI
76
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$6.94M 0.23%
968,881
-22,159
-2% -$167K
ZSPH
77
DELISTED
ZS PHARMA INC COMS TK (DE)
ZSPH
$6.92M 0.23%
132,000
-15,385
-10% -$758K
ATEC icon
78
Alphatec Holdings
ATEC
$1.29B
$6.88M 0.23%
415,228
– –
STDY
79
DELISTED
SteadyMed Ltd
STDY
$6.74M 0.22%
1,267,577
-156
-0% -$1.26K
SCYX icon
80
SCYNEXIS
SCYX
$39M
$6.09M 0.2%
8,660
+2,500
+41% +$1.79M
BEAT
81
DELISTED
BioTelemetry, Inc.
BEAT
$6.08M 0.2%
644,300
– –
TCON
82
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
$5.5M 0.18%
2,425
– –
ALDX icon
83
Aldeyra Therapeutics
ALDX
$105M
$5.36M 0.18%
+690,538
New +$5.95M
STRM
84
DELISTED
Streamline Health Solutions
STRM
$5.1M 0.17%
121,517
– –
DBVT
85
DBV Technologies
DBVT
$852M
$4.77M 0.16%
16,026
-13,786
-46% -$3.56M
TRIB
86
Trinity Biotech
TRIB
$6.53M
$4.74M 0.16%
+52,498
New +$4.55M
BITI
87
DELISTED
BIOTIE THERAPIES CORP SPONSORED ADR
BITI
$4.38M 0.15%
+219,558
New +$4.58M
VCYT icon
88
Veracyte
VCYT
$4.65B
$4.27M 0.14%
+383,256
New +$3.77M
CASM
89
DELISTED
CAS Medical Systems, Inc.
CASM
$4.1M 0.14%
3,200,000
– –
IART icon
90
Integra LifeSciences
IART
$1.49B
$4.01M 0.13%
+145,487
New +$3.88M
TRIL
91
DELISTED
Trillium Therapeutics Inc.
TRIL
$3.76M 0.13%
172,307
-53,757
-24% -$1.23M
PRQR icon
92
ProQR Therapeutics
PRQR
$243M
$3.49M 0.12%
209,398
– –
MZOR
93
DELISTED
Mazor Robotics Ltd.
MZOR
$3.47M 0.12%
261,000
+219,139
+523% +$2.81M
CDTX
94
DELISTED
Cidara Therapeutics
CDTX
$3.33M 0.11%
+11,879
New +$3.65M
IVTY
95
DELISTED
Invuity, Inc
IVTY
$3.09M 0.1%
+218,523
New +$3.18M
WINT
96
DELISTED
Windtree Therapeutics Inc
WINT
$2.49M 0.08%
261,407
– –
NVTA
97
DELISTED
Invitae Corporation
NVTA
$2.48M 0.08%
166,666
– –
APYX icon
98
Apyx Medical
APYX
$172M
$1.92M 0.06%
688,229
-11,771
-2% -$32.4K
KIN
99
DELISTED
Kindred Biosciences, Inc.
KIN
$1.9M 0.06%
279,204
– –
PTN
100
Palatin Technologies
PTN
$15.9M
$1.78M 0.06%
1,600
– –
2 3
4
5 6

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q2 2015 Portfolio in Review

As of Q2 2015, Deerfield Management held 152 positions worth $3B, down 2.8% from $3.09B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Deerfield Management withdrew a net $518M in Q2 2015, closing 32 positions and reducing 33 holdings. Its most notable exit was AUSPEX PHARMACEUTICALS INC COM STK (DE), an estimated $446M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 71% of assets, up from 60% a quarter earlier, followed by Financials and Technology.

Against the trend, Deerfield Management opened a new position in Alpine Immune Sciences Inc worth $56.5M.

  • Deerfield Management's largest Q2 2015 buy was Alpine Immune Sciences Inc: 933,103 shares worth $56.5M.
  • Deerfield Management added most to Viatris in Q2 2015, an estimated $60.8M increase.
  • Deerfield Management's biggest Q2 2015 reduction was bluebird bio, cutting an estimated $47.9M.
  • Deerfield Management fully exited AUSPEX PHARMACEUTICALS INC COM STK (DE) in Q2 2015, selling an estimated $446M.
  • Deerfield Management's ten largest holdings make up 36% of its $3B portfolio in Q2 2015.
  • Deerfield Management opened 30 new positions and closed 32 in Q2 2015.
  • Deerfield Management's portfolio value fell 2.8% quarter-over-quarter to $3B.

Based on Deerfield Management's 13F filing for Q2 2015, filed 14 Aug 2015.